Analysis evaluates the impact of cytogenetic abnormalities on survival in symptomatic multiple myeloma patients, suggesting critical prognostic insights.
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (n=338, 72%) was 6.5 years, patients with del(17p) (n=42, 9%) was 4.4 years, patients with t(4;14) or t(14;16) (n=72, 15%) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (n=18, 4%) was 2.1 years (p=0.032). Patients with double-positive CAs had a significantly worse prognosis.
No takes yet. Share an insight, caveat, or question.
Nakaya et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: